Lantheus Holdings, Inc. (LNTH)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	4,882	6,220	4,246	3,439	1,956	902
Market Cap Growth	56.95%	46.48%	23.46%	75.88%	116.78%	12.06%
Enterprise Value	4,558	5,975	4,250	3,367	2,060	1,039
Last Close Price	70.57	89.46	62.00	50.96	28.89	13.49
PE Ratio	19.99	19.91	13.00	122.54	-	-
Forward PE	10.50	13.87	10.51	12.47	38.18	80.92
PS Ratio	3.18	4.06	3.28	3.68	4.60	2.66
PB Ratio	4.19	5.72	5.21	7.69	4.21	1.75
P/TBV Ratio	5.14	7.19	7.05	48.67	35.73	11.34
P/FCF Ratio	12.45	15.09	19.90	1001.59	46.81	230.01
P/OCF Ratio	9.30	11.42	13.91	12.21	36.27	55.02
PEG Ratio	1.62	1.63	0.70	0.71	1.64	6.47
EV/Sales Ratio	2.97	3.90	3.28	3.60	4.84	3.06
EV/EBITDA Ratio	8.85	11.70	7.68	40.02	-	29.61
EV/EBIT Ratio	10.08	13.40	8.61	93.01	-	99.88
EV/FCF Ratio	11.63	14.49	19.92	980.39	49.31	264.91
Debt / Equity Ratio	0.53	0.57	0.76	1.31	0.42	0.47
Debt / EBITDA Ratio	1.16	1.18	1.10	6.64	-	6.52
Debt / FCF Ratio	1.57	1.51	2.90	170.56	4.63	60.93
Asset Turnover	0.79	0.85	0.87	0.86	0.49	0.53
Inventory Turnover	7.96	8.26	9.34	10.01	6.70	6.18
Quick Ratio	5.19	5.13	5.33	2.54	2.08	1.66
Current Ratio	5.74	5.52	5.80	2.74	2.61	2.29
Return on Equity (ROE)	24.11%	32.82%	51.73%	6.16%	-14.57%	-4.29%
Return on Assets (ROA)	14.55%	15.35%	20.75%	2.07%	-4.80%	1.02%
Return on Capital (ROIC)	16.91%	17.73%	24.99%	2.68%	-5.90%	1.22%
Return on Capital Employed (ROCE)	25.00%	25.60%	33.70%	3.40%	-	1.30%
Earnings Yield	5.21%	5.02%	7.69%	0.82%	-3.65%	-1.49%
FCF Yield	8.03%	6.63%	5.03%	0.10%	2.14%	0.43%
Buyback Yield / Dilution	-1.65%	-2.01%	0.61%	-4.72%	-24.66%	-34.95%

Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q